Form 4: Neurocrine Biosciences Director Exercises Options and Sells Shares Under 10b5-1 Plan
SEC Form 4
Director George J. Morrow exercised stock options and sold 40,000 shares of Neurocrine Biosciences (NBIX) common stock on March 14, 2024, under a pre-arranged 10b5-1 trading plan.
Summary
- On March 14, 2024, George J. Morrow, a director of Neurocrine Biosciences, exercised non-qualified stock options to acquire 40,000 shares of common stock at an exercise price of $39.79 per share.
- Simultaneously, Morrow sold 40,000 shares of Neurocrine Biosciences common stock at a weighted average price of approximately $139.42 and $139.41 per share.
- The transactions were executed under a Rule 10b5-1 trading plan adopted on December 14, 2023.
- Following these transactions, Morrow holds no shares of common stock directly.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing simply reports transactions executed under a pre-existing trading plan. There is no indication of positive or negative sentiment towards the company's prospects.
Industry Context
Sales by insiders are a normal part of corporate governance, especially when executed under pre-arranged trading plans like Rule 10b5-1, which are designed to prevent accusations of insider trading. The market typically views these sales in the context of the overall health and prospects of the company.
Comparison to Industry Standards
- Rule 10b5-1 trading plans are a common practice among corporate insiders at companies like Amgen, Biogen, and Gilead Sciences to diversify their holdings and manage personal finances.
- The volume of shares sold is relatively small compared to the total outstanding shares of Neurocrine Biosciences, suggesting it is unlikely to have a significant impact on the stock price.
- The weighted average sale price is consistent with recent trading prices for NBIX, indicating the sale was executed at market rates.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership, but the pre-planned nature of the sales mitigates concerns about insider trading.
- Employees are unlikely to be directly affected by these transactions.
Key Dates
| Date | Description |
|---|---|
| 09/30/2015 | Date options were granted. |
| 12/14/2023 | Date the 10b5-1 trading plan was adopted. |
| 03/14/2024 | Date of the stock option exercise and share sale. |
| 03/15/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.